{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:56:14Z","timestamp":1792806974052,"version":"4.5.0"},"reference-count":175,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Melanoma is one of the most malignant cancers, and the global incidence of cutaneous melanoma is increasing. While melanomas are highly prone to metastasize if diagnosed late, early detection and treatment significantly reduce the risk of mortality. Identifying patients at higher risk of metastasis, who might benefit from early adjuvant therapies, is particularly important, especially with the advent of new melanoma treatments. Therefore, there is a pressing need to develop additional prognostic biomarkers for melanoma to improve early stratification of patients and accurately identify high-risk subgroups, ultimately enabling more effective personalized treatments. Recent advances in melanoma therapy, including targeted treatments and immunotherapy, have underscored the importance of biomarkers in determining prognosis and predicting treatment response. The clinical application of these markers holds the potential for significant advancements in melanoma management. Various tumor-derived genetic, proteomic, and cellular components are continuously released into the bloodstream of cancer patients. These molecules, including circulating tumor DNA and RNA, proteins, tumor cells, and immune cells, are emerging as practical and precise liquid biomarkers for cancer. In the current era of effective molecular-targeted therapies and immunotherapies, there is an urgent need to integrate these circulating biomarkers into clinical practice to facilitate personalized treatment. This review highlights recent discoveries in circulating melanoma biomarkers, explores the challenges and potentials of emerging technologies for liquid biomarker discovery, and discusses future directions in melanoma biomarker research.<\/jats:p>","DOI":"10.3390\/cancers16244219","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T09:43:03Z","timestamp":1734514983000},"page":"4219","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Melanoma\u2019s New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma"],"prefix":"10.3390","volume":"16","author":[{"given":"Ivana","family":"Prka\u010din","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mislav","family":"Mokos","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3647-3390","authenticated-orcid":false,"given":"Nikola","family":"Ferara","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirna","family":"\u0160itum","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Sestre Milosrdnice University Hospital Center, 10000 Zagreb, Croatia"},{"name":"School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia"},{"name":"Croatian Academy of Sciences and Arts, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1158\/1078-0432.CCR-20-4092","article-title":"The state of melanoma: Emergent challenges and opportunities","volume":"27","author":"Atkins","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_2","unstructured":"American Cancer Society (2024, October 12). Cancer Facts and Figures 2024. Available online: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2024\/2024-cancer-facts-and-figures-acs.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: Current status and future prospects","volume":"1","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40291-022-00628-9","article-title":"Pitfalls in cutaneous melanoma diagnosis and the need for new reliable markers","volume":"27","author":"Lam","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cafiero, F., and De Cian, F. (2021). Histopathological Examination: The Keystone of Treatment of Melanoma. Current Management of Melanoma, Springer.","DOI":"10.1007\/978-3-030-45347-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1600-0560.2007.00891.x","article-title":"Immunohistochemical characteristics of melanoma","volume":"35","author":"Ohsie","year":"2008","journal-title":"J. Cutan. Pathol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s40291-018-0318-z","article-title":"Emerging biomarkers in cutaneous melanoma","volume":"22","author":"Eisenstein","year":"2018","journal-title":"Mol. Diagn. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","article-title":"Cutaneous malignant melanoma: Update on diagnostic and prognostic biomarkers","volume":"36","author":"Abbas","year":"2014","journal-title":"Am. J. Dermatopathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/jocmr2424w","article-title":"Novel drugs and combination therapies for the treatment of metastatic melanoma","volume":"8","author":"Vennepureddy","year":"2016","journal-title":"J. Clin. Med. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Proietti, I., Skroza, N., Michelini, S., Mambrin, A., Balduzzi, V., Bernardini, N., Marchesiello, A., Tolino, E., Volpe, S., and Maddalena, P. (2020). BRAF inhibitors: Molecular targeting and immunomodulatory actions. Cancers, 12.","DOI":"10.3390\/cancers12071823"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","article-title":"Molecular pathways and mechanisms of BRAF in cancer therapy","volume":"28","author":"Poulikakos","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","article-title":"Long-term outcomes in patients with BRAF V600\u2013mutant metastatic melanoma who received dabrafenib combined with trametinib","volume":"36","author":"Long","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Al Hmada, Y., Brodell, R.T., Kharouf, N., Flanagan, T.W., Alamodi, A.A., Hassan, S.Y., Shalaby, H., Hassan, S.L., Haikel, Y., and Megahed, M. (2024). Mechanisms of melanoma progression and treatment resistance: Role of cancer stem-like cells. Cancers, 16.","DOI":"10.3390\/cancers16020470"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ziogas, D.C., Theocharopoulos, C., Lialios, P.P., Foteinou, D., Koumprentziotis, I.A., Xynos, G., and Gogas, H. (2023). Beyond CTLA-4 and PD-1 inhibition: Novel immune checkpoint molecules for melanoma treatment. Cancers, 15.","DOI":"10.3390\/cancers15102718"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1200\/JCO.23.02355","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study","volume":"42","author":"Luke","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11864-022-00948-2","article-title":"Promising blood-based biomarkers for melanoma: Recent progress of liquid biopsy and its future perspectives","volume":"23","author":"Kanemaru","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Puglisi, R., Bellenghi, M., Pontecorvi, G., Pallante, G., Car\u00e8, A., and Mattia, G. (2021). Biomarkers for diagnosis, prognosis and response to immunotherapy in melanoma. Cancers, 13.","DOI":"10.3390\/cancers13122875"},{"key":"ref_23","first-page":"256","article-title":"Cancer biomarker discovery and validation","volume":"4","author":"Goossens","year":"2015","journal-title":"Transl. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000074430","article-title":"Lactate dehydrogenase isoenzymes 1 and 5: Differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors","volume":"24","author":"Koukourakis","year":"2003","journal-title":"Tumor Biol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-94-017-7215-0_8","article-title":"The actual role of LDH as tumor marker, biochemical and clinical aspects","volume":"Volume 867","author":"Scatena","year":"2015","journal-title":"Advances in Cancer Biomarkers"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kocianova, E., Piatrikova, V., and Golias, T. (2022). Revisiting the Warburg Effect with Focus on Lactate. Cancers, 14.","DOI":"10.3390\/cancers14246028"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: Implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00403-022-02425-0","article-title":"An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: Prognostic capabilities and demographic variability","volume":"315","author":"Desai","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: A pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ejca.2015.09.007","article-title":"Prognostic score for patients with advanced melanoma treated with ipilimumab","volume":"51","author":"Diem","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Michetti, F., Clementi, M.E., di Liddo, R., Valeriani, F., Ria, F., Rende, M., di Sante, G., and Romano Spica, V. (2023). The S100B protein: A multifaceted pathogenic factor more than a biomarker. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119605"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jnc.14574","article-title":"The S100B story: From biomarker to active factor in neural injury","volume":"148","author":"Michetti","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Janka, E.A., V\u00e1rv\u00f6lgyi, T., Sipos, Z., So\u00f3s, A., Hegyi, P., Kiss, S., Dembrovszky, F., Csupor, D., K\u00e9ringer, P., and P\u00e9csi, D. (2021). Predictive performance of serum S100B versus LDH in melanoma patients: A systematic review and meta-analysis. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.772165"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1357-2725(01)00046-2","article-title":"S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles","volume":"33","author":"Donato","year":"2001","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejso.2007.04.009","article-title":"A review of the S100 proteins in cancer","volume":"34","author":"Salama","year":"2008","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000135492","article-title":"Long-term survival analysis in metastatic melanoma: Serum S100B is an independent prognostic marker and superior to LDH","volume":"31","author":"Egberts","year":"2008","journal-title":"Onkologie"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/12034754231188434","article-title":"Surveillance after a previous cutaneous melanoma diagnosis: A scoping review of melanoma follow-up guidelines","volume":"27","author":"Johnston","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1046\/j.1365-2133.2002.04691.x","article-title":"Serum S100 concentrations are not useful in predicting micrometastatic disease in cutaneous malignant melanoma","volume":"146","author":"Acland","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2133.2000.03650.x","article-title":"Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma","volume":"143","author":"Jury","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00008390-199604000-00008","article-title":"Prognostic value of serum analyses of S-100\u03b2 protein in malignant melanoma","volume":"6","author":"Hansson","year":"1996","journal-title":"Melanoma Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00008390-199710000-00005","article-title":"S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma","volume":"7","author":"Karnell","year":"1997","journal-title":"Melanoma Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41416-018-0167-x","article-title":"S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies","volume":"119","author":"Wagner","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.intimp.2016.09.030","article-title":"Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy","volume":"40","author":"Felix","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1249559","DOI":"10.1080\/2162402X.2016.1249559","article-title":"Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab","volume":"5","author":"Damuzzo","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1073\/pnas.091601698","article-title":"Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins","volume":"98","author":"Lougheed","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0749.2005.00274.x","article-title":"Melanoma inhibitory activity (MIA): An important molecule in melanoma development and progression","volume":"18","author":"Bosserhoff","year":"2005","journal-title":"Pigment Cell Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"843214","DOI":"10.1155\/2014\/843214","article-title":"Prognostic value of melanoma inhibitory activity protein in localized cutaneous malignant melanoma","volume":"2014","author":"Sandru","year":"2014","journal-title":"J. Skin Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bolovan, L.M., Ceausu, M., Stanciu, A.E., Panait, M.E., Busca, A., Hotnog, C.M., Bleotu, C., Gales, L.N., Georgescu, M.T., and Prunoiu, V.M. (2023). Correlation studies between S100 protein level and soluble MIA or tissue MelanA and gp100 (HMB45) expression in cutaneous melanoma. J. Pers. Med., 13.","DOI":"10.3390\/jpm13060898"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e24840","DOI":"10.1097\/MD.0000000000024840","article-title":"The value of melanoma inhibitory activity and LDH with melanoma patients in a Chinese population","volume":"100","author":"Li","year":"2021","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cca.2013.11.034","article-title":"Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients","volume":"429","author":"Sanmamed","year":"2014","journal-title":"Clin. Chim. Acta"},{"key":"ref_51","first-page":"5033","article-title":"Comparison of the serum tumor markers S100 and melanoma-inhibitory ativity (MIA) in the monitoring of patients with metastatic melanoma receiving vaccination immunotherapy with dendritic cells","volume":"37","author":"Uslu","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"ref_53","first-page":"455","article-title":"Vascular endothelial growth factor (VEGF)\u2014Key factor in normal and pathological angiogenesis","volume":"59","author":"Melincovici","year":"2018","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1080\/02648725.2023.2166708","article-title":"Value of dual-source CT dual-energy parameters combined with serum detection of VEGF and CEA in the diagnosis of early lung cancer","volume":"39","author":"Ren","year":"2023","journal-title":"Biotechnol. Genet. Eng. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/CBM-201745","article-title":"The expression and diagnostic value of serum levels of EphA2 and VEGF-A in patients with colorectal cancer","volume":"31","author":"Wang","year":"2021","journal-title":"Cancer Biomark."},{"key":"ref_56","first-page":"4192","article-title":"Correlations of serum homocysteine, VEGF and gastrin 17 with gastric cancer and precancerous lesiopanns","volume":"23","author":"Zhao","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_57","first-page":"6610769","article-title":"Serum cytokine profiles of melanoma patients and their association with tumor progression and metastasis","volume":"2021","author":"Wang","year":"2021","journal-title":"J. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"8277","DOI":"10.1007\/s13277-015-3564-2","article-title":"Serum markers in early-stage and locally advanced melanoma","volume":"36","author":"Lugowska","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12032-008-9058-y","article-title":"Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma","volume":"25","author":"Tas","year":"2008","journal-title":"Med. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"122563","DOI":"10.1016\/j.lfs.2024.122563","article-title":"VEGF\/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives","volume":"345","author":"Malekan","year":"2024","journal-title":"Life Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1158\/2326-6066.CIR-13-0163","article-title":"Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab","volume":"2","author":"Yuan","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinbiochem.2018.07.003","article-title":"The multiple functions and mechanisms of osteopontin","volume":"59","author":"Icer","year":"2018","journal-title":"Clin. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1468-3083.2011.04210.x","article-title":"Osteopontin expression in plasma of melanoma patients and in melanocytic tumours","volume":"26","author":"Maier","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"V\u00e1rv\u00f6lgyi, T., Janka, E.A., Sz\u00e1sz, I., Koroknai, V., Toka-Farkas, T., Szab\u00f3, I.L., V\u00e1nyai, B., Szegedi, A., Emri, G., and Bal\u00e1zs, M. (2023). Combining biomarkers for the diagnosis of metastatic melanoma. J. Clin. Med., 13.","DOI":"10.3390\/jcm13010174"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3892\/or.2013.2666","article-title":"Plasma osteopontin concentrations in patients with cutaneous melanoma","volume":"30","author":"Filia","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00262-015-1686-4","article-title":"Evaluation of serum osteopontin level and gene polymorphism as biomarkers: Analyses from the Nordic Adjuvant Interferon alpha Melanoma trial","volume":"64","author":"Prasmickaite","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-3-030-38315-2_2","article-title":"Interleukin-8 in the tumor immune niche: Lessons from comparative oncology","volume":"1240","author":"Kim","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Rizzo, M., Varnier, L., Pezzicoli, G., Pirovano, M., Cosmai, L., and Porta, C. (2022). IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.990568"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13046-024-02969-1","article-title":"Blood-based biomarkers in patients with non-small cell lung cancer treated with immune checkpoint blockade","volume":"43","author":"Tsai","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/ijms12031505","article-title":"IL8 and cathepsin B as melanoma serum biomarkers","volume":"12","author":"Zhang","year":"2011","journal-title":"Int. J. Mol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sanmamed","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ced.12164","article-title":"Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: Relevance to early vitiligo","volume":"39","author":"Miniati","year":"2014","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00008390-199908000-00007","article-title":"Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin","volume":"9","author":"Singh","year":"1999","journal-title":"Melanoma Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.08.004","article-title":"Interleukin-8 in cancer pathogenesis, treatment and follow-up","volume":"60","author":"Alfaro","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"42031","DOI":"10.18632\/oncotarget.9662","article-title":"IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib","volume":"7","author":"Fernando","year":"2016","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","article-title":"Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors","volume":"7","author":"Bilusic","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.iotech.2022.100311","article-title":"200MO Anti\u2013IL-8 BMS-986253 + nivolumab (NIVO) \u00b1 ipilimumab (IPI) in patients (pts) with advanced cancer: Update of initial phase I results","volume":"16","author":"Simonelli","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Baber, M.A., Crist, C.M., Devolve, N.L., and Patrone, J.D. (2023). Tyrosinase Inhibitors: A Perspective. Molecules, 28.","DOI":"10.3390\/molecules28155762"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00008390-199504000-00007","article-title":"Tyrosinase activity in the serum of patients with malignant melanoma","volume":"5","author":"Sonesson","year":"1995","journal-title":"Melanoma Res."},{"key":"ref_81","first-page":"293","article-title":"Detection of tyrosinase mRNA from the blood of melanoma patients","volume":"5","author":"Stevens","year":"1996","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1515\/CCLM.2006.260","article-title":"Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: Correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics","volume":"44","author":"Mitropapas","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000086973","article-title":"Serum protein s-100 predicts clinical outcome in patients with melanoma treated with adjuvant interferon\u2014Comparison with tyrosinase rt-PCR","volume":"68","author":"Molina","year":"2005","journal-title":"Oncology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-019-0523-2","article-title":"Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients","volume":"7","author":"Diem","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","first-page":"120","article-title":"Serum TA90 immune complex assay can predict outcome after resection of thick (\u22654 mm) primary melanoma and sentinel lymphadenectomy","volume":"9","author":"Chung","year":"2002","journal-title":"Ann. Surg. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2003.08.012","article-title":"Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors","volume":"198","author":"Litvak","year":"2004","journal-title":"J. Am. Coll. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1200\/JCO.2001.19.4.1176","article-title":"Tumor-Associated Antigen TA90 Immune Complex Assay Predicts Recurrence and Survival After Surgical Treatment of Stage I-III Melanoma","volume":"19","author":"Kelley","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_88","first-page":"364","article-title":"TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma","volume":"3","author":"Hsueh","year":"1997","journal-title":"Cancer J. Sci. Am."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10434-001-0198-y","article-title":"Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma","volume":"8","author":"Tsioulias","year":"2001","journal-title":"Ann. Surg. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/07357900701208634","article-title":"A comparison of 3 tumor markers (MIA, TA90IC, S100B) in stage III melanoma patients","volume":"25","author":"Faries","year":"2007","journal-title":"Cancer Investig."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Blazevic, N., Rogic, D., Pelajic, S., Miler, M., Glavcic, G., Ratkajec, V., Vrkljan, N., Bakula, D., Hrabar, D., and Pavic, T. (2024). YKL-40 as a biomarker in various inflammatory diseases: A review. Biochem. Med., 34.","DOI":"10.11613\/BM.2024.010502"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2019.08.025","article-title":"Measured and genetically predicted plasma YKL-40 levels and melanoma mortality","volume":"121","author":"Ismail","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12935-019-0983-y","article-title":"Prognostic value of YKL-40 in solid tumors: A meta-analysis of 41 cohort studies","volume":"19","author":"Bian","year":"2019","journal-title":"Cancer Cell Int."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhao, H., Huang, M., and Jiang, L. (2023). Potential Roles and Future Perspectives of Chitinase 3-like 1 in Macrophage Polarization and the Development of Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216149"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/1055-9965.EPI-05-0011","article-title":"Serum YKL-40, a new prognostic biomarker in cancer patients?","volume":"15","author":"Johansen","year":"2006","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/CMR.0000000000000237","article-title":"Prognostic and predictive value of YKL-40 in stage IIB-III melanoma","volume":"26","author":"Krogh","year":"2016","journal-title":"Melanoma Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.cardiores.2005.12.002","article-title":"Structure and function of matrix metalloproteinases and TIMPs","volume":"69","author":"Nagase","year":"2006","journal-title":"Cardiovasc. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1124\/pharmrev.121.000349","article-title":"Matrix metalloproteinases: From molecular mechanisms to physiology, pathophysiology, and pharmacology","volume":"74","author":"Thode","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5158","DOI":"10.1158\/1078-0432.CCR-04-2478","article-title":"High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma","volume":"11","author":"Nikkola","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-05-0774","article-title":"Measurement of matrix metalloproteinases in serum of patients with melanoma: Snarled in technical pitfalls","volume":"11","author":"Zucker","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s004320100257","article-title":"Serum matrix metalloproteinase-2 in patients with malignant melanoma","volume":"127","author":"Wollina","year":"2001","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_102","first-page":"1","article-title":"Exploring vitamin D metabolism and function in cancer","volume":"50","author":"Jeon","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.molonc.2011.01.007","article-title":"Melanoma and vitamin D","volume":"5","author":"Field","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.18632\/oncotarget.14316","article-title":"Vitamin D deficiency is associated with a worse prognosis in metastatic melanoma","volume":"8","author":"Timerman","year":"2017","journal-title":"Oncotarget"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jid.2019.05.033","article-title":"Environmental exposures such as smoking and low vitamin d are predictive of poor outcome in cutaneous melanoma rather than other deprivation measures","volume":"140","author":"Hardie","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ad.2021.11.001","article-title":"Prognostic value of vitamin D serum levels in cutaneous melanoma","volume":"113","author":"Moro","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/bjd\/ljae257","article-title":"High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: Results of a randomized double-blind placebo-controlled study (ViDMe trial)","volume":"191","author":"Janssen","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: Current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","article-title":"Liquid biomarkers in melanoma: Detection and discovery","volume":"17","author":"Lim","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1159\/000499337","article-title":"Liquid biopsy: General concepts","volume":"63","author":"Poulet","year":"2019","journal-title":"Acta Cytol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: Biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13073-020-00728-3","article-title":"Tracking cancer progression: From circulating tumor cells to metastasis","volume":"12","author":"Aceto","year":"2020","journal-title":"Genome Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/14737159.2020.1846523","article-title":"Circulating tumor cell clusters: Insights into tumour dissemination and metastasis","volume":"20","author":"Herath","year":"2020","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Strati, A., Markou, A., Kyriakopoulou, E., and Lianidou, E. (2023). Detection and molecular characterization of circulating tumour cells: Challenges for the clinical setting. Cancers, 15.","DOI":"10.3390\/cancers15072185"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Klinac, D., Gray, E.S., Freeman, J.B., Reid, A., Bowyer, S., Millward, M., and Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-423"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2011.40.0887","article-title":"Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial","volume":"30","author":"Hoshimoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"324","DOI":"10.12659\/MSM.904770","article-title":"High number of circulating tumor cells predicts poor survival of cutaneous melanoma patients in China","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-19-2670","article-title":"Circulating tumor cells and early relapse in node-positive melanoma","volume":"26","author":"Lucci","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jamcollsurg.2018.04.026","article-title":"Circulating tumor cells in stage IV melanoma patients","volume":"227","author":"Hall","year":"2018","journal-title":"J. Am. Coll. Surg."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.013","article-title":"Melanoma circulating tumor cells: Benefits and challenges required for clinical application","volume":"424","author":"Marsavela","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"115230","DOI":"10.18632\/oncotarget.23247","article-title":"Circulating cell-free DNA content as blood based biomarker in endometrial cancer","volume":"8","author":"Cicchillitti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Tessier, N.P., Hardy, L.M., Deleuze, J.F., and How-Kit, A. (2023). Circulating cell-free nucleic acids of plasma in human aging, healthy aging and longevity: Current state of knowledge. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1321280"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e159590","DOI":"10.1172\/jci.insight.159590","article-title":"Cell-free DNA topology depends on its subcellular and cellular origins in cancer","volume":"7","author":"Malkin","year":"2022","journal-title":"JCI Insight"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"ii6","DOI":"10.1093\/noajnl\/vdac066","article-title":"A hitchhiker\u2019s guide to cell-free DNA biology","volume":"4","author":"Mouliere","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"M\u0171zes, G., Bohusn\u00e9 Barta, B., Szab\u00f3, O., Horgas, V., and Sipos, F. (2022). Cell-free DNA in the pathogenesis and therapy of non-infectious inflammations and tumors. Biomedicines, 10.","DOI":"10.3390\/biomedicines10112853"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e13015","DOI":"10.1111\/eci.13015","article-title":"High levels of circulating cell-free DNA are a biomarker of active SLE","volume":"48","author":"Xu","year":"2018","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13075-017-1295-z","article-title":"Circulating DNA in rheumatoid arthritis: Pathological changes and association with clinically used serological markers","volume":"19","author":"Rykova","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jdv.16766","article-title":"The predictive and prognostic significance of cell-free DNA concentration in melanoma","volume":"35","author":"Elouali","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","article-title":"Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients","volume":"88","author":"Valpione","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1373\/jalm.2018.026393","article-title":"Circulating tumor DNA for early cancer detection","volume":"3","author":"Fiala","year":"2018","journal-title":"J. Appl. Lab. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: A promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-17-3837","article-title":"The Landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients","volume":"24","author":"Zill","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"FSO295","DOI":"10.4155\/fsoa-2017-0140","article-title":"Kinetics of circulating cell-free DNA for biomedical applications: Critical appraisal of the literature","volume":"4","author":"Khier","year":"2018","journal-title":"Futur. Sci. OA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.22598","article-title":"Detection of mutated BRAFV600E variant in circulating DNA of stage III\u2013IV melanoma patients","volume":"120","author":"Daniotti","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"101072","DOI":"10.1016\/j.tranon.2021.101072","article-title":"The prognostic value of circulating tumor DNA in patients with melanoma: A systematic review and meta-analysis","volume":"14","author":"Feng","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6660571","DOI":"10.1155\/2021\/6660571","article-title":"Prognostic value of ctDNA mutation in melanoma: A meta-analysis","volume":"2021","author":"Zheng","year":"2021","journal-title":"J. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1200\/JCO.2005.02.9876","article-title":"Predictive utility of circulating methylated dna in serum of melanoma patients receiving biochemotherapy","volume":"23","author":"Mori","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1158\/0008-5472.CAN-06-0801","article-title":"Estrogen receptor-\u03b1 methylation predicts melanoma progression","volume":"66","author":"Mori","year":"2006","journal-title":"Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Warburton, L., Reid, A., Amanuel, B., Calapre, L., Millward, M., and Gray, E. (2023). Detectable ctDNA at the time of treatment cessation of ipilimumab and nivolumab for toxicity predicts disease progression in advanced melanoma patients. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1280730"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5926","DOI":"10.1158\/1078-0432.CCR-20-2251","article-title":"Circulating tumor DNA predicts outcome from first-, but not second-line treatment and identifies melanoma patients who may benefit from combination immunotherapy","volume":"26","author":"Marsavela","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Kan, C.M., Pei, X.M., Yeung, M.H.Y., Jin, N., Ng, S.S.M., Tsang, H.F., Cho, W.C.S., Yim, A.K., Yu, A.C., and Wong, S.C.C. (2023). Exploring the role of circulating cell-free RNA in the development of colorectal cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311026"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Hu, H., Song, H., Han, B., Zhao, H., and He, J. (2024). Tumor-educated platelet RNA and circulating free RNA: Emerging liquid biopsy markers for different tumor types. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2902080"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1002\/ctm2.1090","article-title":"Circulating cell-free messenger RNA enables non-invasive pan-tumour monitoring of melanoma therapy independent of the mutational genotype","volume":"12","author":"Albrecht","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jid.2023.01.027","article-title":"N6-methyladenosine RNA methylation correlates with immune microenvironment and immunotherapy response of melanoma","volume":"143","author":"Wang","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1397344","article-title":"Overview of microRNA biology","volume":"35","author":"Mohr","year":"2015","journal-title":"Semin. Liver Dis."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Mumford, S.L., Towler, B.P., Pashler, A.L., Gilleard, O., Martin, Y., and Newbury, S.F. (2018). Circulating microRNA biomarkers in melanoma: Tools and challenges in personalised medicine. Biomolecules, 8.","DOI":"10.3390\/biom8020021"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/0008-5472.CAN-07-2538","article-title":"The promyelocytic leukemia zinc finger\u2013microRNA-221\/-222 pathway controls melanoma progression through multiple oncogenic mechanisms","volume":"68","author":"Felicetti","year":"2008","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Leidinger, P., Keller, A., Borries, A., Reichrath, J., Rass, K., Jager, S.U., Lenhof, H.P., and Meese, E. (2010). High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-262"},{"key":"ref_154","first-page":"3097","article-title":"Decreased serum microRNA-206 level predicts unfavorable prognosis in patients with melanoma","volume":"8","author":"Tian","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ebiom.2015.05.011","article-title":"The prognostic and predictive value of melanoma-related microRNAs using tissue and serum: A microRNA expression analysis","volume":"2","author":"Stark","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.12998\/wjcc.v7.i19.2930","article-title":"Expression and predictive value of miR-489 and miR-21 in melanoma metastasis","volume":"7","author":"Mo","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"117690","DOI":"10.1016\/j.cca.2023.117690","article-title":"Tumor-educated platelets","volume":"552","author":"Najafi","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Liu, Z., Wang, J., Liao, F., Song, Q., and Yao, Y. (2022). Tumor-educated platelets facilitate thrombus formation through migration. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.857865"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-023-02856-1","article-title":"Tumor cell-induced platelet aggregation accelerates hematogenous metastasis of malignant melanoma by triggering macrophage recruitment","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nature22079","article-title":"T-cell invigoration to tumour burden ratio associated with anti-PD-1 response","volume":"545","author":"Huang","year":"2017","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","article-title":"Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejca.2016.12.011","article-title":"Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients","volume":"73","author":"Martens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e006367","DOI":"10.1136\/jitc-2022-006367","article-title":"Liquid biopsies coming of age: Biology, emerging technologies, and clinical translation\u2014An introduction to the JITC expert opinion special review series on liquid biopsies","volume":"11","author":"Stewart","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Horgan, D., \u010cufer, T., Gatto, F., Lugowska, I., Verbanac, D., Carvalho, \u00c2., Lal, J.A., Kozaric, M., Toomey, S., and Ivanov, H.Y. (2022). Accelerating the development and validation of liquid biopsy for early cancer screening and treatment tailoring. Healthcare, 10.","DOI":"10.3390\/healthcare10091714"},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Yan, X., and Liu, C. (2022). Application of non-blood-derived fluid biopsy in monitoring minimal residual diseases of lung cancer. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.865040"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Agashe, R., and Kurzrock, R. (2020). Circulating tumor cells: From the laboratory to the cancer clinic. Cancers, 12.","DOI":"10.3390\/cancers12092361"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/sj.onc.1206460","article-title":"Development of melanocyte precursors from the vertebrate neural crest","volume":"22","author":"Dupin","year":"2003","journal-title":"Oncogene"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Beigi, Y.Z., Lanjanian, H., Fayazi, R., Salimi, M., Hoseyni, B.H.M., Noroozizadeh, M.H., and Masoudi-Nejad, A. (2024). Heterogeneity and molecular landscape of melanoma: Implications for targeted therapy. Mol. Biomed., 5.","DOI":"10.1186\/s43556-024-00182-2"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Fankhauser, R., Chang, M., Garrison, Z., Berryman, R., Lucero, O.M., Fuiten, A., DePatie, N., Seifert, H., and Kulkarni, R.P. (2022). Single-cell identification of melanoma biomarkers in circulating tumor cells. Cancers, 14.","DOI":"10.3390\/cancers14194921"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Arisi, M.F., Dotan, E., and Fernandez, S.V. (2022). Circulating tumor DNA in precision oncology and its applications in colorectal cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084441"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Xu, Z., Qiao, Y., and Tu, J. (2019). Microfluidic technologies for cfDNA isolation and analysis. Micromachines, 10.","DOI":"10.3390\/mi10100672"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1002\/ijc.33481","article-title":"High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment","volume":"148","author":"Okamura","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Kong, S.L., Liu, X., Tan, S.J., Tai, J.A., Phua, L.Y., Poh, H.M., Yeo, T., Chua, Y.W., Haw, Y.X., and Ling, W.H. (2021). Complementary sequential circulating tumor cell (CTC) and cell-free tumor DNA (ctDNA) profiling reveals metastatic heterogeneity and genomic changes in lung cancer and breast cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.698551"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1158\/0008-5472.CAN-21-1718","article-title":"Current and future clinical applications of ctDNA in immuno-oncology","volume":"82","author":"Stadler","year":"2022","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4219\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:54:51Z","timestamp":1760115291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/24\/4219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":175,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16244219"],"URL":"https:\/\/doi.org\/10.3390\/cancers16244219","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}